SINTX Technologies Announces Grant of New U.S Patent For Antibacterial Applications of Silicon Nitride
SINTX Technologies has secured US Patent 10,806,831, which covers antibacterial biomedical implants utilizing silicon nitride. This patent expands the company's capability to enhance the antibacterial properties of various implants, including those made from PEEK and titanium. The company plans to launch a composite product in early 2021. SINTX's silicon nitride can also be used in face masks to neutralize pathogens. This patent strengthens SINTX's intellectual property position in the biomedical sector.
- Granting of US Patent 10,806,831 enhances SINTX's product offerings in biomedical implants.
- The patent allows integration of silicon nitride in widely-used biomaterials such as PEEK and titanium, potentially expanding market reach.
- Antibacterial properties of silicon nitride have been validated by independent studies.
- Development of a composite product which is expected to launch in early 2021.
- Risks associated with the incorporation of silicon nitride into medical products remain uncertain.
- Volatility in stock price may affect investor confidence.
- Uncertainties in new product development and market acceptance pose potential challenges.
SALT LAKE CITY, Oct. 28, 2020 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT) (“SINTX” or the “Company”), a manufacturer of silicon nitride ceramic for medical and non-medical applications, today announced that the United States Patent and Trademark Office has issued US Patent 10,806,831 covering antibacterial biomedical implants and associated materials. This newly issued patent broadly covers a variety of biomedical implants wherein the Company’s silicon nitride is applied to improve the antibacterial characteristics of the implant.
“The antibacterial characteristics of SINTX’s silicon nitride were identified in 2012, and have been confirmed by multiple independent studies. We have developed and tested powders, coatings, and composites of silicon nitride that extend the technology to other material platforms,” said Dr. Sonny Bal President, and CEO of SINTX Technologies.
In the biomedical space, beyond monolithic silicon nitride implants that are already FDA-approved, SINTX can now add its material to widely-used biomaterials such as PEEK and titanium. The Company has already developed a composite of silicon nitride and PEEK and expects to launch the product in early 2021.
SINTX provides silicon nitride in other forms such as sintered powders and soluble fractions, which expand its technology portfolio yet further. The different forms of silicon nitride allow SINTX to include it in a variety of applications such as fabrics for catch-and-kill face masks that can neutralize respiratory pathogens. The newly-issued patent is an important milestone in SINTX’s strategy to leverage the antipathogenic properties of silicon nitride, and it adds to a growing IP portfolio in that space.
About SINTX Technologies, Inc.
SINTX Technologies is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX Technologies is the manufacturing, research, and development of silicon nitride ceramics for external partners. The Company presently manufactures silicon nitride powders and components in its FDA registered and ISO 13485:2016 certified manufacturing facility.
For more information on SINTX Technologies or its silicon nitride material platform, please visit www.sintx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) that are subject to a number of risks and uncertainties. Risks and uncertainties that may cause such differences include, among other things: incorporation of silicon nitride into personal protective equipment and other products may not be safe or effective; volatility in the price of SINTX’s common stock; the uncertainties inherent in new product development, including the cost and time required to commercialize such product(s); market acceptance of our products once commercialized; SINTX’s ability to raise additional funding and other competitive developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 26, 2020, and in SINTX’s other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.
Business Inquiries for SINTX:
SINTX Technologies
801.839.3502
IR@sintx.com
Media Inquiries for SINTX:
Amanda Barry
Associate Director, Content and PR
The Summit Group
abarry@summitslc.com
FAQ
What is the significance of US Patent 10,806,831 for SINT?
When is SINTX expected to launch its new composite product?
What materials can SINTX's silicon nitride be integrated with?
What are the risks associated with SINTX's new product development?
How has SINTX validated the antibacterial properties of silicon nitride?
